June 2026 Research Update

This month, research on Marfan syndrome diagnosis focused on three connected issues: expanding the list of known FBN1 gene changes, understanding that additional gene variants may add to differences between people, and testing non-invasive ways to flag Marfan-like features earlier. Overall, the papers reinforce that genetic results can be clear (pathogenic variants) or uncertain (variants of uncertain significance), and that newer tools like facial scanning are being studied as screening aids rather than stand-alone answers. [1] [2] [3] [4] [5]

Two single-patient reports added to what is known about FBN1 variants linked to Marfan syndrome. One adult male with severe heart and blood vessel features had a newly described truncating frameshift change in FBN1 that was not seen in population databases and met standard classification criteria used for pathogenicity. [1]

In a separate case, a 2-month-old infant with early-onset Marfan syndrome had a de novo (new in the child) pathogenic FBN1 variant and also had multi-suture craniosynostosis (early fusion of multiple skull sutures), a feature that has been reported in early-onset cases but not previously tied to that specific variant. This report highlights that Marfan syndrome can present with unusual early findings in some infants. [5]

A prospective study of 136 Mexican patients with Marfan syndrome and related connective tissue disorders used a broad heart-focused gene panel and often found more than one potentially relevant genetic variant in the same person. The authors described repeated findings in a heart muscle gene (MYBPC3) across several syndromes and suggested that coexisting variants might help explain why cardiovascular findings differ from person to person, but they emphasized important limitations (such as no family segregation testing) and that the results are hypothesis-generating. [2]

One prenatal case report described a fetus with multiple skeletal and cardiac anomalies where genetic testing found variants of uncertain significance (VUS) in FBN1 and PIGL, but parental testing was not available to check whether the variants were new or inherited. The authors cautioned against using VUS alone to make prenatal diagnostic conclusions because uncertainty can remain without additional evidence. [3]

A separate diagnostic-model study tested whether 3D facial scans analyzed with a graph-based computer model could distinguish people with Marfan syndrome from controls. In 440 participants (126 with Marfan syndrome), the model reported high discrimination (area under the curve up to 0.98) and accuracy above 93%, and the authors noted the decision threshold could be tuned to reduce missed cases at the cost of more false alarms. [4]

For patients and families, these studies mainly add context about why genetic results sometimes feel straightforward and sometimes do not. New FBN1 variants continue to be reported in single families or individuals, which can gradually improve interpretation over time, while prenatal VUS results may remain uncertain without more information (such as parental testing). Broad gene panels and research tools like 3D facial scanning may help researchers understand and screen for Marfan syndrome, but how these approaches should be used in routine care, and in which populations, is still not fully established from the evidence here. [1] [2] [3] [4] [5]

In a large single-center study of people who underwent extensive aortic surgery for acute type A aortic dissection, long-term survival was similar in those with and without Marfan syndrome. However, people with Marfan syndrome were more likely to need another operation later, often involving other parts of the aorta. [6]

In a multicenter adult Marfan syndrome cohort (783 people), 58% had at least one cardiac operation and 41% of those who had surgery later required a repeat sternotomy (a repeat opening of the chest). Higher redo risk was linked to high blood pressure, needing an emergency first operation, and having postoperative complications, while a more extensive first aortic repair beyond the aortic root was linked to lower redo odds. [7]

In a high-volume center study of acute type A aortic dissection treated with total arch replacement plus a stented segment in the upper descending aorta (frozen elephant trunk), operative death rates and 10-year survival were similar between Marfan and non-Marfan patients. However, Marfan syndrome patients had more late reoperations over 10 years, mainly from later procedures on the downstream aorta, and they more often had ongoing blood flow in the false channel beyond the stented area. [6]

A smaller cohort study (67 people) reported that a larger preoperative left heart chamber size (left ventricular end-diastolic dimension at least 65 mm) and needing emergency breathing tube placement were linked to higher long-term mortality. In the same study, having a surgical intervention was linked to lower mortality even when the analysis accounted for changes over time, suggesting heart size may add information beyond aortic diameter alone in this surgical referral population. [8]

For patients and caregivers, this group of studies reinforces that Marfan syndrome often involves more than one operation over a lifetime, including later procedures on parts of the aorta away from the initial repair. Much of this evidence comes from retrospective hospital cohorts, so results may differ by center and by which patients were referred. What remains uncertain is how best to predict, for an individual person, who will need repeat operations and how imaging and heart measurements should be combined to estimate long-term risk. [7]

These case reports highlight that aortic and artery problems in Marfan syndrome can present in very different ways, including during late pregnancy and outside the main aorta. They also show that emergency care may involve staged procedures or combined operations, and recovery can range from smooth to complicated, depending on the situation. [9] [10] [11] [12]

One report described a third-trimester pregnancy with probable Marfan syndrome and a complicated type B aortic dissection that reduced blood flow to abdominal organs. During cesarean delivery, surgeons performed an open bypass to the artery supplying the intestines, and follow-up scans over 3 years showed a stable dissection and an open bypass graft, with the patient asymptomatic on follow-up. [9]

Another pregnancy case involved a 23-year-old at 35 weeks with Marfan syndrome and sickle cell trait who developed an acute type A aortic dissection and underwent cesarean delivery and aortic repair during the same operation using a heart-lung machine. The repair was successful, but the postoperative course included several complications (including breathing problems and heart strain), and later imaging showed a remaining type B dissection. [10]

A 19-year-old man with early-onset Marfan syndrome had a complicated type B dissection with poor blood flow to both legs and was treated first with emergency stent-graft repair, then with a later open thoracoabdominal aortic replacement after rapid enlargement of the aorta was seen on scans. He recovered without stroke or spinal cord injury, but had postoperative pneumonia and breathing limitation that required a temporary tracheostomy and a long hospital stay. [11]

A separate case described a 57-year-old woman with previously unrecognized Marfan syndrome who presented with aneurysms of both subclavian (arm) arteries, including a contained rupture on the left side. She underwent staged endovascular repairs with follow-up imaging at 6 weeks showing open stents without leak, and genetic testing later confirmed an FBN1-related Marfan diagnosis; the authors noted that long-term durability of this approach in Marfan syndrome is not yet proven. [12]

For patients, these reports mainly serve as background examples of the range of emergencies that can occur in Marfan syndrome, including during pregnancy and involving arteries outside the aorta. Because each paper describes a single person, the outcomes cannot predict what will happen for others, and the long-term performance of some endovascular repairs in Marfan syndrome remains uncertain. They also illustrate that recovery after emergency aortic care can include significant short-term complications in some situations, even when the repair itself is successful. [11]

Across these reports, pregnancy-related aortic dissection remained a major concern in Marfan syndrome, and genetic subtype may help explain risk differences that aortic root size alone did not capture. [13] Evidence on a pre-pregnancy aortic root support procedure came from only two women, so it cannot show how well it works in broader groups. [14]

In a retrospective cohort of 35 women with genetically confirmed Marfan syndrome, pregnancy-related aortic dissection occurred more often in those with haploinsufficient FBN1 variants than in those with non-haploinsufficient variants. [13] Most dissections were Stanford type B (involving the descending aorta), and pre-pregnancy aortic root diameters were similar in women with and without dissection. [13]

The same cohort noted other factors seen among women who dissected, including being undiagnosed with Marfan syndrome at the time of dissection and not being on beta-blocker therapy, but the study was not designed to prove cause and effect. [13] The authors suggested that FBN1 variant type could add information beyond aortic root size when discussing pregnancy-related dissection risk. [13]

In a case series of three pregnancies in two women who had preconception Personalized External Aortic Root Support (PEARS), no aortic dissections occurred and aortic measurements stayed stable during pregnancy and follow-up. [14] All deliveries were vaginal and newborn outcomes were described as favorable, but all cases had postpartum hemorrhage due to retained placenta. [14]

For patients and families planning pregnancy, this month’s research mainly adds context for risk discussions: one center’s experience suggests the specific type of FBN1 gene change may matter for pregnancy-related aortic dissection risk, including dissections outside the aortic root. [13] The PEARS report is early, based on very few pregnancies, and it also highlights that pregnancy outcomes can include non-aortic complications such as postpartum bleeding, so larger studies are still needed to understand who benefits and what trade-offs exist. [14]

Across this months papers, outcomes differed by the type of heart procedure. In adults with Marfan syndrome treated for atrial fibrillation or flutter, abnormal rhythm often came back after catheter ablation and some people had procedure-related complications. In contrast, a separate single-patient report described a combined aorta and valve operation where heart ultrasound during and after surgery supported a valve-preserving approach with only small residual valve leakage. [15] [16]

In a multicenter retrospective study of catheter ablation for atrial fibrillation or flutter in Marfan syndrome, most rhythm-targeted atrial fibrillation ablations had recurrence over time, and nearly half needed at least one repeat ablation. Recurrence was reported for both paroxysmal and persistent atrial fibrillation groups. The study also reported a substantial overall complication rate, including bleeding or vascular problems and several less common but serious events. [15]

The same study reported that ablation for typical atrial flutter (a different rhythm problem) had lower recurrence than rhythm-targeted atrial fibrillation ablation in this cohort. It also described that some patients required pacemakers, and among those with pacemakers, device-related problems such as lead issues or infection were reported, along with cases of pacing-induced weakening of the heart muscle. [15]

A case report described one 23-year-old woman with Marfan syndrome and complex heart disease who had combined mitral and tricuspid valve repair plus aortic root replacement. The surgical team used epicardial echocardiography (ultrasound on the surface of the heart during surgery) to guide decisions, and postoperative imaging showed mild aortic valve leakage and only trace leakage of the mitral and tricuspid valves at discharge. Because this is a single case, the result may not apply to others with different anatomy or severity. [16]

For patients and caregivers, these papers mainly add context about what has been reported after procedures for rhythm problems and valve disease in Marfan syndrome, rather than changing care. The ablation study suggests that return of atrial rhythm problems and repeat procedures were common in this specific Marfan cohort, and it documents types of complications that occurred, but it cannot prove what would happen for any individual or how it compares with other groups. The valve surgery report shows what was achievable in one carefully described situation and highlights the role of detailed heart ultrasound during surgery, but it is background evidence because it is only one patient and does not show longer-term durability.

Across these studies, the overall pattern was that surgery for a dislocated or unstable natural lens in Marfan syndrome can improve vision, but long-term stability of the artificial lens and the amount of leftover focusing error remain ongoing concerns. Evidence came from retrospective studies (looking back at past care), including small Marfan-specific series and one large electronic health record study. The main uncertainties are how results compare between techniques and which surgical details best reduce later complications in real-world patients. [17] [18] [19] [20]

In a small study of Marfan patients having capsular tension ring (CTR)-assisted cataract surgery with a single-focus artificial lens, a specific angle measurement during surgery was linked to how much astigmatism remained afterward. Angles below 50 degrees were tied to higher leftover astigmatism, while angles at or above 50 degrees did not show a clear relationship, suggesting there may be a threshold where this measurement matters most. [19]

In a Marfan case series of scleral-fixated artificial lenses (both sutured and a sutureless technique called Yamane), average best-corrected vision improved after surgery. Complications happened in 4 of 15 eyes, including one retinal detachment and several cases where the lens shifted or was caught by the pupil, and these were handled with additional operations; two eyes had limited improvement because of pre-existing amblyopia (reduced vision from early-life visual development). [17]

In children with non-traumatic ectopia lentis (most due to Marfan syndrome) treated with lens removal and a rigid scleral-fixated artificial lens, both near and distance vision improved over about 6.5 years of follow-up. Refractive error shifted away from very strong nearsightedness toward mild nearsightedness over time, but visually significant lens implant subluxation still occurred in 14% of eyes and sometimes required reoperation. [18]

A large electronic health record study of cataract surgery patients (not limited to Marfan syndrome) reported that intraocular lens dislocation occurred in 1.1% of patients from 2020 to 2024 and increased steadily over the last two decades. The study also reported that ocular trauma, eye injections into the gel of the eye, and prior vitrectomy increased over time, and Marfan syndrome was among the risk factors evaluated. [20]

For patients and caregivers, this month’s research mainly adds context about what tends to improve (vision) and what may still happen over time (lens implant shifting, leftover astigmatism, and in some cases retinal detachment) after surgery for lens problems in Marfan syndrome. Some results are specific to certain operations (CTR-assisted cataract surgery, scleral-fixated lenses, and pediatric ectopia lentis surgery), and they come from retrospective studies, so they cannot fully predict outcomes for an individual. What remains uncertain is which technique or surgical details most reliably reduce later lens movement and refractive changes, especially over many years and across different ages.

Across these studies, fibrillin proteins (key building blocks in connective tissue) were connected to how tissues hold together and how cells respond to their surrounding support structure. The work points to specific ways fibrillin changes could affect the lining around the spinal cord and how certain cells commit to becoming fat cells, but these are early-stage results and not direct patient care studies. [21] [22] [23]

In a study of 42 people with type 1b spontaneous spinal cerebrospinal fluid (CSF) leaks, rare gene changes in FBN2 (the gene for fibrillin-2) were more common than in several control groups. In lab testing, some of these fibrillin-2 variants reduced how well fibrillin-2 fragments could stick to human dura fibroblasts (cells from the tissue layer surrounding the spinal cord), and mice engineered to carry similar variants had a higher risk of dural rupture after a controlled leak trigger. [21]

Another preclinical study focused on how fibrillin-1 in the extracellular matrix can influence early steps in fat cell development. An engineered fibrillin-1 fragment with an active cell-binding site (RGD) slowed early adipogenic commitment through a specific integrin signal and downstream pathways, while a similar fragment without that active site did not; blocking that signaling reversed the effect in the lab. [22]

A separate methods paper created three induced pluripotent stem cell lines from skin cells of people with Marfan syndrome who carry FBN1 mutations. These lab-grown cells showed expected stem cell features and could develop into multiple cell types, providing a platform that other researchers can use to model Marfan-related cardiovascular biology in a dish. [23]

For patients and caregivers, this theme is mainly background research about how changes in connective-tissue proteins might influence different organs beyond the aorta, such as the tissue around the spinal cord, and how cells respond to their surrounding support structure. The genetic study strengthens the idea that fibrillin-2 can contribute to spinal CSF leak risk in some people, but it does not establish how often this applies in Marfan syndrome overall. The cell and animal studies help map possible biological pathways and create lab tools, but they do not by themselves change monitoring or treatment decisions.

Across mostly exploratory lab and animal studies, researchers tested multiple possible drivers of Marfan-related heart and blood vessel changes, including immune cells, lymphatic drainage, and molecular signaling that affects the vessel wall. Several studies identified pathways that might limit or worsen tissue remodeling, but results varied by target and model, and most evidence is not from people with Marfan syndrome. [24] [25] [26] [27] [28]

In a Marfan mouse model focused on the mitral valve, valve lymphatic vessels developed poorly after birth, drainage was impaired, and immune cells (MHCII+ macrophages) were widespread in the valve. Treatments that boosted lymphatic signaling (VEGF-C156S) or changed immune cell movement and lymphatic junctions (fingolimod, also called FTY720) improved lymphatic measures and reduced myxomatous mitral valve degeneration in this model. [24]

An aging study in a common Marfan mouse model reported that the thoracic aortic aneurysm grew from early life to 1 year, then showed near growth arrest from 1 to 2 years. The authors reported gene and signaling changes during this later period, including lower levels of Ltbp3 and Rictor, and highlighted changes in transforming growth factor-beta (TGF-beta) and mTOR signaling as areas to watch for how aneurysm expansion might slow. [25]

Two studies tested molecular targets tied to aortic wall remodeling. In one Marfan mouse study, stachydrine treatment reduced aortic widening and tissue damage in the aorta, along with lower LDHA levels and reduced measures linked to matrix breakdown and TGF-beta activity; rescue experiments supported LDHA as part of the chain of effects. [26] In an ex vivo study using human aneurysm tissue stimulated with TGF-beta to mimic Marfan-like changes, losartan lowered a small RNA marker (miR-632) and certain degeneration markers, but some drug combinations reduced that effect, while directly blocking miR-632 had stronger effects on several remodeling readouts in this model. [27]

Not all proposed targets showed benefit in aortic disease models. In a Marfan mouse study and related cell experiments, forcing higher levels of asprosin (a peptide derived from fibrillin-1) in endothelial cells did not change aortic size or elastin quality over the study period, and it did not meaningfully shift most inflammation or cell-transition markers, suggesting no protective effect in that setup. [28]

For patients, these studies help explain why Marfan-related damage may differ by organ (aorta vs mitral valve) and why immune activity and lymphatic drainage are being studied alongside classic connective-tissue pathways. Most of this evidence comes from mice or lab models (including a short-term human tissue model), so it mainly informs future research directions rather than current care. It also highlights uncertainty: some biological ideas did not show benefit when tested (asprosin), and results in controlled models may not match long-term, whole-body disease in people.